Sareum

Sareum is a drug discovery company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and auto-immune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum’s Chk1 kinase cancer research programme is a joint research collaboration with The Institute of Cancer Research and Cancer Research Technology Limited. The development candidate resulting from the collaboration increases the effectiveness of current cancer therapeutics in several in-vivo cancer models.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum’s drug discovery technology platform that has so far produced the Company’s Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange and trades under the symbol SAR.

Come and see us at booth #73

Website:
www.sareum.com
Company Type
Dr Tim Mitchell

SCM Pharma

SCM Pharma is a UK-based contract pharmaceutical organisation (CMO) that works with clients progressing drugs through clinical trials and others that require ongoing small-medium scale commercial supply of licensed products.

With expertise in novel, difficult and dangerous products and medical devices requiring complex fill/finish, the specialist CMO provides a wide range of sterile and non-sterile development, manufacturing and packaging services to meet client needs. These services include terminal sterilisation, aseptic processing (including biologicals and radio-labelled molecules) and handling highly potent products including cytotoxics and cytostatic.

Come and see us at booth #73

Company Type
Ms Joanne Anderson
Business Development Manager 

Selcia

Selcia Limited is a leading worldwide provider of contract research services. Our headquarters are in Ongar, Essex and we have a branch in Hopkinton, MA. Selcia operates two divisions, Selcia Discovery, which provides integrated small molecule drug discovery to pharmaceutical and biotech clients, and Selcia Radiolabeling which specializes in 14C GMP radiolabelling.

In addition to general medicinal chemistry and biology capabilities applicable across a range of target classes, Selcia Discovery has particular strengths in three unique and highly synergistic technologies:
(1) medicinal chemistry of complex natural products
(2) capillary electrophoresis-based fragment and natural product screening
(3) PPI targets in particular peptidyl-prolyl isomerase targets (including cyclophilins, FKBPs, Pin1, together called PPIases).
Whilst relatively neglected by pharmaceutical companies in the past, understanding of the involvement of PPIases in many diseases is currently emerging. All PPIase inhibitors presently in clinical use or in development are natural products, natural product derivatives or have structures inspired by natural products.


The combination of these technologies has enabled Selcia to deliver several clinical PPIase inhibitors to clients, but has also generated IP for Selcia, which we have recently demerged into a new company, Mitopharm Limited who are in advanced license negotiations for a breakthrough drug in the field of acute and chronic neurodegenerative diseases. Other applications in the fields of chronic inflammatory diseases, oncology, COPD, and virus infections will be developed by Mitopharm either via investment or via joint R&D programs with pharmaceutical companies.

We have also recently established Selcia Pharma, a spin out company focussed on the optimisation/preclinical development and partnering of Selcia’s preclinical antimicrobial (antibacterial & antifungal) assets.

Come and see us at booth #73

Website:
www.selcia.com
Company Type
Mr Dave Roberts
Mr Simon Bury

Sera Laboratories International

Seralab is a leading supplier of biological material to Life Science.

The company offers the most complete range of human and animal-based bioproducts in Europe. Seralab supplies serum, plasma, whole blood, tissues, tissue homogenates,hepatocytes, microsomes, S9 fractions and fluids from the human model and an extensive range of animal species.

Human disease state material includes serum, plasma, whole blood, CSF and other tissue and fluid samples from donors with a wide range of diseases including autoimmune disease and cancer states.
Pre-clinical Research tools are also available from healthy, treated or diseased animals, in the form of cells, fluids or tissues, from a wide range of validated animal models of human inflammatory diseases used by Pharmaceutical companies , for example Asthma, Alzheimer’s and Rheumatoid Arthritis.

Other products include Cell Culture sera and reagents including Foetal Bovine Serum, Cell Specific media selected growth factors and Stem Cell reagents.

Our UK Production company APS Ltd offers a range of Custom Services, including Sterile Filtration and bottling, Buffer Production, Monoclonal and Polyclonal Antibody Production, Kit Manufacture and many other services, tailored to meet your outsourcing requirements.

Seralab is looking to introduce the company and products/service to a wider audience and to investigate possibilities for collaboration.

Company Type